Levro Infusion contains Levetiracetam 100 mg/ml, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Administered intravenously, Levro Infusion provides rapid and effective seizure control, particularly in patients unable to take oral medication. The mechanism of action involves modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, which reduces neuronal excitability and seizure propagation. Levro Infusion is typically used as an adjunctive therapy or monotherapy depending on clinical judgment. The infusion should be administered under medical supervision, with dosing individualized based on patient response, renal function, and clinical condition. Common adverse effects include somnolence, dizziness, headache, and fatigue, while serious reactions such as hypersensitivity or psychiatric symptoms are rare but require prompt evaluation. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Levro Infusion is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients. Proper monitoring of neurological status and renal function is recommended during therapy to ensure safety and efficacy.